Loading organizations...
§ Private Profile · San Clemente, CA, USA
ROX Medical is a technology company.
ROX Medical develops a novel interventional vascular device, the ROX Coupler, designed to treat patients suffering from resistant hypertension. This implantable device establishes a small, controlled connection between the external iliac artery and vein, aiming to reduce blood pressure by altering vascular resistance. The system offers a minimally invasive approach for individuals whose hypertension remains uncontrolled despite conventional medical therapies.
The company was co-founded in 2004 by Rodney Brenneman, who served as V.P. of R&D and Board Secretary. The core insight behind its formation stemmed from the critical need for alternative treatment strategies for severe hypertension, recognizing that a direct vascular intervention could address physiological mechanisms resistant to pharmaceutical management. Brenneman brought extensive experience in medical device development to the venture, shaping the development of the Coupler technology.
The ROX Coupler serves patients with persistent, severe hypertension, offering a new therapeutic option when other treatments have failed to achieve adequate blood pressure control. ROX Medical’s vision centers on improving patient outcomes by providing an effective, adjunctive treatment that can significantly lower blood pressure and mitigate the long-term risks associated with uncontrolled hypertension, thereby addressing a substantial unmet medical need in cardiovascular health.
ROX Medical has raised $95.0M across 5 funding rounds.
ROX Medical has raised $95.0M in total across 5 funding rounds.
ROX Medical has raised $95.0M in total across 5 funding rounds.
ROX Medical's investors include Apple Tree Partners, Steven Weinstein, Andera Partners, Domain Associates, Forbion, T1D Fund, Versant Ventures.
ROX Medical has raised $95.0M across 5 funding rounds. Most recently, it raised $40.0M Series E in September 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2016 | $40M Series E | Apple Tree Partners, Steven Weinstein | Andera Partners, Domain Associates, Forbion, T1D Fund | Announced |
| Sep 7, 2012 | $6M Venture Round | — | Domain Associates, Versant Ventures | Announced |
| Sep 1, 2012 | $6M Series D | — | Domain Associates, T1D Fund, Versant Ventures | Announced |
| Jun 1, 2008 | $33M Series C | — | Domain Associates, T1D Fund | Announced |
| Jul 1, 2006 | $10M Series B | — | Domain Associates, T1D Fund | Announced |
ROX Medical is a privately held medical device company developing the ROX Coupler, an innovative interventional vascular therapy for patients with uncontrolled hypertension. The device enables a minimally invasive, reversible procedure performed in under one hour in a standard catheterization lab, without sedation, targeting the over 16 million Americans on medication yet failing to control blood pressure[2][3]. It serves patients with resistant hypertension (e.g., stage 2 >160 mmHg), physicians in vascular labs, and healthcare systems addressing a major cardiovascular challenge affecting 67 million U.S. adults, with proven 12-month outcomes showing mean drops of 27 mmHg (office) and 13 mmHg (ambulatory) in the ROX CONTROL HTN study published in *The Lancet*[2]. Growth momentum includes commercial availability in Europe under CE mark and ongoing U.S. studies, positioning it as a potential major advance per experts like Dr. Melvin Lobo[2].
ROX Medical emerged as a pioneer in hypertension therapy, based in San Clemente, California, with a focus on interventional solutions for uncontrolled cases where drugs fail[2][3]. Key leadership includes CEO Rodney Brenneman, who highlighted the unmet need for five million U.S. stage 2 hypertension patients in 2017 announcements[2]. The company's pivotal moment came with the 2017 publication of 12-month ROX CONTROL HTN study results in *The Lancet*, validating durable blood pressure reductions and sparking recognition as a "major advance"[2]. Early traction built on this evidence, leading to European commercialization and further trials, humanizing its mission through clinician endorsements and patient impact data[2][3].
(Note: Distinct from RoX Health, a German healthcare innovation studio[1].)
ROX Medical rides the wave of interventional cardiology advancements for cardiovascular diseases, a top global killer, where digital and device innovations target heart failure, obesity, and hypertension amid rising prevalence[1][2]. Timing aligns with limitations of oral therapies—failing 16 million medicated U.S. patients—fueling demand for minimally invasive options like renal denervation alternatives[2]. Market forces favor it: aging populations, CDC-highlighted epidemics, and post-*Lancet* validation drive clinician adoption and payer interest[2]. It influences the ecosystem by expanding outpatient hypertension management, potentially reducing hospitalizations and inspiring hybrid device-drug therapies in medtech.
ROX Medical's path forward hinges on U.S. FDA approval, leveraging CONTROL HTN data and additional trials to capture resistant hypertension market share[2]. Trends like personalized vascular interventions and AI-enhanced diagnostics will amplify its impact, especially as obesity-hypertension links grow[1][2]. Influence may evolve from niche therapy to standard-of-care, transforming uncontrolled hypertension outcomes and echoing its *Lancet*-proven promise as a "major advance" for millions[2].